GLP1R and Parkinson disease: Preliminary investigation into therapeutic targeting of reactive astrocyte sub-states has been leveraged in mouse models of PD where abatement of immune cell dysfunction, and mitigation of astrocyte-induced neuron cell death appears possible using glucagon-like 1 peptide receptor agonists.